Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: A longitudinal perfusion fMRI study

Drug and Alcohol Dependence

Volumn 117, Issue 2-3, 2011, Pages 176-183

  Franklin, Teresa R ^a   Wang, Ze ^a   Sciortino, Nathan ^a   Harper, Derek ^a   Li, Yin ^a   Hakun, Jonathan ^a   Kildea, Susan ^a   Kampman, Kyle ^a   Ehrman, Ron ^a   Detre, John A ^a   O'Brien, Charles P ^a   Childress, Anna Rose ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Addiction; Baclofen; Cerebral blood flow; GABA B agonist; Limbic circuitry; Resting baseline perfusion fMRI

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; PLACEBO;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE TITRATION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; LONGITUDINAL STUDY; MALE; MOTIVATION; ORBITAL CORTEX; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REST; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SMOKING CESSATION; SMOKING HABIT; SPIN LABELING; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; BACLOFEN; BASAL GANGLIA; BRAIN; CEREBROVASCULAR CIRCULATION; FEMALE; GABA-B RECEPTOR AGONISTS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PERFUSION; PLACEBOS; PREFRONTAL CORTEX; TIME FACTORS; YOUNG ADULT;

EID: 79959938791     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.01.015     Document Type: Article

References (77)

1. Addolorato G., Caputo F., Capristo E., Colombo G., Gessa G.L., Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II-preliminary clinical evidence. Alcohol Clin. Exp. Res. 2000, 24:67-71.
2. Addolorato G., Leggio L., Ferrulli A., Cardone S., Vonghia L., Mirijello A., Abenavoli L., D'Angelo C., Caputo F., Zambon A., Haber P.S., Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.
3. Agabio R., Marras P., Addolorato G., Carpiniello B., Gessa G.L. Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. J. Clin. Psychopharmacol. 2007, 27:319-320.
4. Aguirre G.K., Detre J.A., Wang J. Perfusion fMRI for functional neuroimaging. Int. Rev. Neurobiol. 2005, 66:213-236.
5. Aisen M.L., Dietz M.A., Rossi P., Cedarbaum J.M., Kutt H. Clinical and pharmacokinetic aspects of high dose oral baclofen therapy. J. Am. Paraplegia. Soc. 1992, 15:211-216.
6. Alsop D.C., Detre J.A. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J. Cereb. Blood Flow Metab. 1996, 16:1236-1249.
7. Assadi S.M., Radgoodarzi R., Ahmadi-Abhari S.A. Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]. BMC Psychiatry 2003, 3:16.
8. Balfour D.J., Wright A.E., Benwell M.E., Birrell C.E. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav. Brain Res. 2000, 113:73-83.
9. Bearden C.E., Thompson P.M., Dutton R.A., Frey B.N., Peluso M.A., Nicoletti M., Dierschke N., Hayashi K.M., Klunder A.D., Glahn D.C., Brambilla P., Sassi R.B., Mallinger A.G., Soares J.C. Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology 2008, 33:1229-1238.
10. Benowitz N.L., Gourlay S.G. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J. Am. Coll. Cardiol. 1997, 29:1422-1431.
11. Bonson K.R., Grant S.J., Contoreggi C.S., Links J.M., Metcalfe J., Weyl H.L., Kurian V., Ernst M., London E.D. Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 2002, 26:376-386.
12. Boyke J., Driemeyer J., Gaser C., Buchel C., May A. Training-induced brain structure changes in the elderly. J. Neurosci. 2008, 28:7031-7035.
13. Brebner K., Childress A.R., Roberts D.C. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol. 2002, 37:478-484.
14. Brody A.L., Mandelkern M.A., Jarvik M.E., Lee G.S., Smith E.C., Huang J.C., Bota R.G., Bartzokis G., London E.D. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol. Psychiatry 2004, 55:77-84.
15. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., O'Brien C.P. Limbic activation during cue-induced cocaine craving. Am. J. Psychiatry 1999, 156:11-18.
16. Colombo G., Agabio R., Carai M.A., Lobina C., Pani M., Reali R., Addolorato G., Gessa G.L. Ability of baclofen in reducing alcohol intake and withdrawal severity: I-preclinical evidence. Alcohol Clin. Exp. Res. 2000, 24:58-66.
17. Corrigall W.A., Coen K.M., Adamson K.L., Chow B.L., Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl.) 2000, 149:107-114.
18. Corrigall W.A., Coen K.M., Zhang J., Adamson K.L. GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology (Berl.) 2001, 158:190-197.
19. Craig A.D. How do you feel-now? The anterior insula and human awareness. Nat. Rev. Neurosci. 2009, 10:59-70.
20. Devinsky O., Morrell M.J., Vogt B.A. Contributions of anterior cingulate cortex to behaviour. Brain 1995, 118:279-306.
21. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 2000, 393:295-314.
22. Domino E.F., Minoshima S., Guthrie S., Ohl L., Ni L., Koeppe R.A., Zubieta J.K. Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. Synapse 2000, 38:313-321.
23. Driemeyer J., Boyke J., Gaser C., Buchel C., May A. Changes in gray matter induced by learning-revisited. PLoS. One 2008, 3:e2669.
24. Duvernoy H.M. The Human Brain: Surface, Three-Dimensional Sectional Anatomy with Magnetic Resonance Imaging and Blood Supply 1999, Springer-Verlag, Wien, New York.
25. Elliott R., Dolan R.J., Frith C.D. Dissociable functions in the medial and lateral orbitofrontal cortex: evidence from human neuroimaging studies. Cereb. Cortex 2000, 10:308-317.
26. Enrico P., Bouma M., de Vries J.B., Westerink B.H. The role of afferents to the ventral tegmental area in the handling stress-induced increase in the release of dopamine in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Brain Res. 1998, 779:205-213.
27. Fadda P., Scherma M., Fresu A., Collu M., Fratta W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003, 50:1-6.
28. Fagerstrom K.O., Schneider N.G. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J. Behav. Med. 1989, 12:159-182.
29. Fattore L., Cossu G., Martellotta M.C., Fratta W. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol 2002, 37:495-498.
30. Franklin T.R., Wang Z., Wang J., Sciortino N., Harper D., Li Y., Ehrman R., Kampman K., O'Brien C.P., Detre J.A., Childress A.R. Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology 2007, 32:2301-2309.
31. Franklin T.R., Harper D., Kampman K., Kildea-McCrea S., Jens W., Lynch K.G., O'Brien C.P., Childress A.R. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend. 2009, 103:30-36.
32. Franklin T.R., Lohoff F.W., Wang Z., Sciortino N., Harper D., Li Y., Jens W., Cruz J., Kampman K., Ehrman R., Berrettini W., Detre J.A., O'Brien C.P., Childress A.R. DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology 2009, 34:717-728.
33. Franklin T.R., Wang Z., Suh J., Hazan R., Cruz J., Li Y., Goldman M., Detre J.A., O'Brien C.P., Childress A. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch. Gen. Psychiatry 2011, 10.1001/archgenpsychiatry.2010.190.
34. Franklin, T.R., Wang, Z., Li, Y., Suh, J., Goldman, M., Lohoff, F., Cruz, J., Hazan, R., Jens, W., Detre, J.A., Berretini, W., O'Brien, C.P., Childress, A.R., 2011b. Dopamine transporter genotype modulation of neural responses to smoking cues: Confirmation in a new cohort. Addiction Biology 2011, doi:10.1111/j.1369-1600.2010.00277.x.
35. Gazdzinski S., Durazzo T.C., Studholme C., Song E., Banys P., Meyerhoff D.J. Quantitative brain MRI in alcohol dependence: preliminary evidence for effects of concurrent chronic cigarette smoking on regional brain volumes. Alcohol Clin. Exp. Res. 2005, 29:1484-1495.
36. Grant S., London E.D., Newlin D.B., Villemagne V.L., Liu X., Contoreggi C., Phillips R.L., Kimes A.S., Margolin A. Activation of memory circuits during cue-elicited cocaine craving. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:12040-12045.
37. Griffiths R.R., Lamb R.J., Sannerud C.A., Ator N.A., Brady J.V. Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology (Berl.) 1991, 103:154-161.
38. Gudeman D., Shoptaw S., Majewska D., Scherf S., Yeats D., Ling W. Preliminary report of Baclofen as a cocaine craving medication. Proceedings of the Problems of Drug Dependence 1996 1997.
39. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Cooper Z.D., Foltin R.W. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl.) 2010, 211:233-244.
40. Haubenstock A., Hruby K., Jager U., Lenz K. Baclofen (Lioresal) intoxication report of 4 cases and review of the literature. J. Toxicol. Clin. Toxicol. 1983, 20:59-68.
41. Heinzerling K.G., Shoptaw S., Peck J.A., Yang X., Liu J., Roll J., Ling W. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006, 85:177-184.
42. Hermes M., Hagemann D., Britz P., Lieser S., Rock J., Naumann E., Walter C. Reproducibility of continuous arterial spin labeling perfusion MRI after 7 weeks. MAGMA 2007, 20:103-115.
43. Hughes J.R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob. Res. 2007, 9:315-327.
44. Johnson B.A., Swift R.M., Addolorato G., Ciraulo D.A., Myrick H. Safety and efficacy of GABAergic medications for treating alcoholism. Alcohol Clin. Exp. Res. 2005, 29:248-254.
45. Kahn R., Biswas K., Childress A.R., Shoptaw S., Fudala P.J., Gorgon L., Montoya I., Collins J., McSherry F., Li S.H., Chiang N., Alathari H., Watson D., Liberto J., Beresford T., Stock C., Wallace C., Gruber V., Elkashef A. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend. 2009, 103:59-64.
46. http://www.rxlist.com/cgi/generic/baclofen_ad.htm Index, R.T.i.D., 2010. Kemstro, Side Effects and Drug Interactions. Accessed on http://www.rxlist.com/cgi/generic/baclofen_ad.htm.
47. Kilts C.D., Schweitzer J.B., Quinn C.K., Gross R.E., Faber T.L., Muhammad F., Ely T.D., Hoffman J.M., Drexler K.P. Neural activity related to drug craving in cocaine addiction. Arch. Gen. Psychiatry 2001, 58:334-341.
48. Kringelbach M.L., Rolls E.T. The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog. Neurobiol. 2004, 72:341-372.
49. Kumari V., Gray J.A., ffytche D.H., Mitterschiffthaler M.T., Das M., Zachariah E., Vythelingum G.N., Williams S.C., Simmons A., Sharma T. Cognitive effects of nicotine in humans: an fMRI study. Neuroimage 2003, 19:1002-1013.
50. Ling W., Shoptaw S., Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 1998, 18:403-404.
51. Mai J.K., Voss T., Paxinos G. Atlas of the Human Brain 2008, Elsevier Academic Press, New York; London.
52. Malcolm R.J. GABA systems, benzodiazepines, and substance dependence. J. Clin. Psychiatry 2003, 64(Suppl. (3)):36-40.
53. Markou A., Paterson N.E., Semenova S. Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation. Ann. N. Y. Acad. Sci. 2004, 1025:491-503.
54. McClernon F.J., Hiott F.B., Huettel S.A., Rose J.E. Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology 2005, 30(10):1940-1947.
55. Naqvi N.H., Rudrauf D., Damasio H., Bechara A. Damage to the insula disrupts addiction to cigarette smoking. Science 2007, 315:531-534.
56. Paterson N.E., Froestl W., Markou A. The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl.) 2004, 172:179-186.
57. Penny W., Friston K. Mixtures of general linear models for functional neuroimaging. IEEE Trans Med Imaging 2003, 22(4):504-514.
58. Physician's Desk Reference, 1993. Montvale: Medical Economics Data 47th edition.
59. Robbins S.J., Ehrman R.N., Childress A.R., O'Brien C.P. Relationships among physiological and self-report responses produced by cocaine-related cues. Addict. Behav. 1997, 22:157-167.
60. Roberts D.C., Andrews M.M. Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure. Psychopharmacology (Berl.) 1997, 131:271-277.
61. Rolls E.T. The functions of the orbitofrontal cortex. Brain Cogn. 2004, 55:11-29.
62. Schneider F., Habel U., Wagner M., Franke P., Salloum J.B., Shah N.J., Toni I., Sulzbach C., Honig K., Maier W., Gaebel W., Zilles K. Subcortical correlates of craving in recently abstinent alcoholic patients. Am. J. Psychiatry 2001, 158:1075-1083.
63. Sheehan B., Lecrubier Y., Sheehan K. The Mini International Neuropsychiatric Interview (MINI): the development and validation of structured diagnostic interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:22-33.
64. Shoaib M., Swanner L.S., Beyer C.E., Goldberg S.R., Schindler C.W. The GABAB agonist baclofen modifies cocaine self-administration in rats. Behav. Pharmacol. 1998, 9:195-206.
65. Shoptaw S., Yang X., Rotheram-Fuller E.J., Hsieh Y.C., Kintaudi P.C., Charuvastra V.C., Ling W. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J. Clin. Psychiatry 2003, 64:1440-1448.
66. Sim M.E., Lyoo I.K., Streeter C.C., Covell J., Sarid-Segal O., Ciraulo D.A., Kim M.J., Kaufman M.J., Yurgelun-Todd D.A., Renshaw P.F. Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects. Neuropsychopharmacology 2007, 32:2229-2237.
67. Small D.M., Zatorre R.J., Dagher A., Evans A.C., Jones-Gotman M. Changes in brain activity related to eating chocolate: from pleasure to aversion. Brain 2001, 124:1720-1733.
68. Spano M.S., Fattore L., Fratta W., Fadda P. The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology 2007, 52:1555-1562.
69. Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., Hawkins M., Rao S.M., Bandettini P.A., Bloom A.S. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiatry 1998, 155:1009-1015.
70. Taricco M., Adone R., Pagliacci C., Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst. Rev 2000, CD001131.
71. Vogt B.A., Sikes R.W. The medial pain system, cingulate cortex, and parallel processing of nociceptive information. Prog. Brain Res. 2000, 122:223-235.
72. Wang Z., Faith M., Patterson F., Tang K., Kerrin K., Wileyto E.P., Detre J.A., Lerman C. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J. Neurosci. 2007, 27:14035-14040.
73. Wang Z., Aguirre G.K., Rao H., Wang J., Fernandez-Seara M.A., Childress A.R., Detre J.A. Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx. Magn. Reson. Imaging 2008, 26:261-269.
74. Westerink B.H., Enrico P., Feimann J., De Vries J.B. The pharmacology of mesocortical dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and prefrontal cortex of the rat brain. J. Pharmacol. Exp. Ther. 1998, 285:143-154.
75. Wilson S.J., Sayette M.A., Delgado M.R., Fiez J.A. Instructed smoking expectancy modulates cue-elicited neural activity: a preliminary study. Nicotine Tob. Res. 2005, 7:637-645.
76. Yoshida M., Yokoo H., Tanaka T., Emoto H., Tanaka M. Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. Brain Res. 1994, 636:111-114.
77. Yucel K., Taylor V.H., McKinnon M.C., Macdonald K., Alda M., Young L.T., MacQueen G.M. Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology 2008, 33:361-367.